367 related articles for article (PubMed ID: 31965542)
1. Conjunctival Melanoma: Current Treatments and Future Options.
Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
[TBL] [Abstract][Full Text] [Related]
2. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
Zhou AY; Johnson DB
Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
[TBL] [Abstract][Full Text] [Related]
4. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
5. Two cases of BRAF-mutated, bulbar conjunctival melanoma, and review of the published literature.
Kiyohara T; Tanimura H; Miyamoto M; Shijimaya T; Nagano N; Nakamaru S; Makimura K; Iwai H
Clin Exp Dermatol; 2020 Mar; 45(2):207-211. PubMed ID: 31361915
[TBL] [Abstract][Full Text] [Related]
6. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401
[TBL] [Abstract][Full Text] [Related]
7. Melanoma: smart therapeutic strategies in immuno-oncology.
Eggermont AM; Robert C
Nat Rev Clin Oncol; 2014 Apr; 11(4):181-2. PubMed ID: 24590131
[No Abstract] [Full Text] [Related]
8. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
Dulgar O; Kutuk T; Eroglu Z
Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
[TBL] [Abstract][Full Text] [Related]
9. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T; Kim KB
Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
[TBL] [Abstract][Full Text] [Related]
10. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
Yu C; Liu X; Yang J; Zhang M; Jin H; Ma X; Shi H
Front Immunol; 2019; 10():990. PubMed ID: 31134073
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients.
Sheng X; Li S; Chi Z; Si L; Cui C; Mao L; Lian B; Tang B; Wang X; Yan X; Kong Y; Dai J; Guo J
Br J Ophthalmol; 2015 Jul; 99(7):990-6. PubMed ID: 25595173
[TBL] [Abstract][Full Text] [Related]
12. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
Schaefer T; Satzger I; Gutzmer R
Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapies for Melanoma: A New Standard of Care?
Smalley KS; Eroglu Z; Sondak VK
Am J Clin Dermatol; 2016 Apr; 17(2):99-105. PubMed ID: 26860106
[TBL] [Abstract][Full Text] [Related]
14. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
Miller DM; Flaherty KT; Tsao H
Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
[TBL] [Abstract][Full Text] [Related]
15. Management of Metastatic Melanoma in 2018.
Kaufman HL; Margolin K; Sullivan R
JAMA Oncol; 2018 Jun; 4(6):857-858. PubMed ID: 29621376
[No Abstract] [Full Text] [Related]
16. Clinical treatment options for early-stage and advanced conjunctival melanoma.
Zeng Y; Hu C; Shu L; Pan Y; Zhao L; Pu X; Wu F
Surv Ophthalmol; 2021; 66(3):461-470. PubMed ID: 32980421
[TBL] [Abstract][Full Text] [Related]
17. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
Meng D; Carvajal RD
Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374
[TBL] [Abstract][Full Text] [Related]
18. Advances in the Immunobiological Therapies for Advanced Melanoma.
Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
[TBL] [Abstract][Full Text] [Related]
19. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]